Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
# Purpose of Review Attention deficit hyperactivity disorder (ADHD) is a widely diagnosed neurodevelopmental disorder giving rise to symptoms of hyperactivity, impulsivity, and inattentiveness that can impair daily functioning. Stimulants, such as methylphenidate and amphetamines, are the mainstay...
Saved in:
Main Authors: | Christopher L Robinson, Katelyn Parker, Saurabh Kataria, Evan Downs, Rajesh Supra, Alan D. Kaye, Omar Viswanath, Ivan Urits |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Medical Publishing
2022-09-01
|
Series: | Health Psychology Research |
Online Access: | https://doi.org/10.52965/001c.38360 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Daridorexant for the Treatment of Insomnia
by: Christopher L Robinson, et al.
Published: (2022-08-01) -
Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update
by: Hannah W Haddad, et al.
Published: (2022-07-01) -
Attention-Deficit/Hyperactivity Disorder (ADHD)
by: Garret D. Evans, et al.
Published: (2006-08-01) -
Attention-Deficit/Hyperactivity Disorder (ADHD)
by: Garret D. Evans, et al.
Published: (2006-08-01) -
Prenatal Acetaminophen Exposure and its Associated Risk for Attention Deficit Hyperactivity Disorder
by: Noah J. Spillers, et al.
Published: (2024-11-01)